Pallas Capital Advisors’s Akebia Therapeutics AKBA Stock Holding History

Pallas Capital Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.2K	Buy	+12,474	New	+$14.8K	﹤0.01%	1020

Other funds holding AKBA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Pallas Capital Advisors's AKBA Position: Q2 2026 in Review

Pallas Capital Advisors opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 12,474 shares worth $14.2K. The stake represents ﹤0.01% of the portfolio and ranks #1020 among its holdings.

171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

Pallas Capital Advisors held 12,474 shares of Akebia Therapeutics worth $14.2K as of Q2 2026.
Akebia Therapeutics was a new Pallas Capital Advisors position in Q2 2026.
Akebia Therapeutics made up ﹤0.01% of Pallas Capital Advisors's portfolio in Q2 2026, its #1020 holding.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.